Nasdaq · Biotech stocks database
NAII — Natural Alternatives International Inc. ☆
NAII (Natural Alternatives International Inc.) stock: $1.01, $7.4M cash, $6.3M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Overview
Catalysts
Assets
Pipeline
Trials
Holders
News
What they do
Our vision is to enrich the world through the best of nutrition. We are a leading formulator, manufacturer and marketer of nutritional supplements.
Source: 10-K FY2026 via SEC EDGAR
Enterprise value
Not disclosed
Balance sheet
Cash $7.4M Debt $0.0M Net cash $7.4M Enterprise value Not disclosed Basic shares 6.3M shares Fully diluted shares 6.3M shares Fully diluted market cap $6.3M Cash per share $1.18 Quarterly burn $1.1M Cash runway 6.9 quarters
Cash figures as of 2026-06-30. Database snapshot: 2026-11-11.
Share structure
Cap table as of 2026-09-28.
Price history Loading NAII daily closes…
Loading price history…
Asset data not yet available for this company.
No lead program on file for this company.
Active clinical trials Trial Phase Status Role Sponsor BP Condition(s) Mgmt guide NCT01439659 Phase 2 Active, not recruiting Collaborator M.D. Anderson Cancer Center — Ovarian Cancer —
Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
View all 1 active trials for M.D. Anderson Cancer Center on ClinicalTrials.gov
Specialist fund holders Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Fully Diluted · Free biotech stocks database. Figures are sourced from SEC filings and company disclosures; not investment advice.